» Articles » PMID: 29445407

Practical Outpatient Pharmacotherapy for Alcohol Use Disorder

Overview
Journal Drugs Context
Specialty Pharmacology
Date 2018 Feb 16
PMID 29445407
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Alcohol use disorder (AUD) is commonly encountered in clinical practice. A combination of psychosocial intervention and pharmacotherapy is the cornerstone of AUD treatment. Despite their efficacy, safety and cost-effectiveness, clinicians are reluctant to prescribe medications to treat individuals with AUD. Given the high rate of relapse with psychosocial intervention alone, increasing patient access to this underutilized treatment has the potential to improve clinical outcome in this difficult-to-treat population. Herein, we provide practical pharmacotherapy strategies to improve treatment outcome for AUD. We review the efficacy and side effects of both on- and off-label agents with a particular focus on clinical applicability. Recommendations are supported by findings from randomized controlled trials (RCT) and meta-analyses selected to be representative, where possible, of current treatment guidelines. The goal of this paper is to help readers use pharmacotherapy with greater confidence when treating patients with AUD.

Citing Articles

Alcoholic cardiomyopathy: an update.

Dominguez F, Adler E, Garcia-Pavia P Eur Heart J. 2024; 45(26):2294-2305.

PMID: 38848133 PMC: 11231944. DOI: 10.1093/eurheartj/ehae362.


Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma.

Barsouk A, Aluru J, Rawla P, Saginala K, Barsouk A Med Sci (Basel). 2023; 11(2).

PMID: 37367741 PMC: 10304137. DOI: 10.3390/medsci11020042.


The use of medications approved for alcohol use disorders in Italy.

Fortinguerra F, Pierantozzi A, Trotta F Front Public Health. 2023; 11:1110435.

PMID: 36875354 PMC: 9975714. DOI: 10.3389/fpubh.2023.1110435.


The Effects of Citalopram and Thalamic Dopamine D Receptor Availability on Decision-Making and Loss Aversion in Alcohol Dependence.

Zorick T, Okita K, Renard K, Mandelkern M, Brody A, London E Psychiatry J. 2022; 2022:5663274.

PMID: 36249526 PMC: 9553840. DOI: 10.1155/2022/5663274.


The Added Value of Pharmacotherapy to Cognitive Behavior Therapy And Vice Versa in the Treatment of Alcohol Use Disorders: A Systematic Review.

van Amsterdam J, Blanken P, Spijkerman R, van den Brink W, Hendriks V Alcohol Alcohol. 2022; 57(6):768-775.

PMID: 36085572 PMC: 9651984. DOI: 10.1093/alcalc/agac043.


References
1.
Kyzar E, Pandey S . Molecular mechanisms of synaptic remodeling in alcoholism. Neurosci Lett. 2015; 601:11-9. PMC: 4506731. DOI: 10.1016/j.neulet.2015.01.051. View

2.
Kleber H, Weiss R, Anton R, Rounsaville B, George T, Strain E . Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry. 2006; 163(8 Suppl):5-82. View

3.
Akbar M, Egli M, Cho Y, Song B, Noronha A . Medications for alcohol use disorders: An overview. Pharmacol Ther. 2017; 185:64-85. PMC: 5898984. DOI: 10.1016/j.pharmthera.2017.11.007. View

4.
Fuller R, Branchey L, Brightwell D, Derman R, Emrick C, Iber F . Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986; 256(11):1449-55. View

5.
Mason B, Quello S, Goodell V, Shadan F, Kyle M, Begovic A . Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2013; 174(1):70-7. PMC: 3920987. DOI: 10.1001/jamainternmed.2013.11950. View